Search the site

The Kids respiratory, anaesthesia and mental health researchers secure vital funding

The Kids Research Institute Australia researchers have been awarded $5.3 million in prestigious Investigator Grants from the National Health and Medical Research Council

Protection against severe infant lower respiratory tract infections by immune training: Mechanistic studies

Results from recent clinical studies suggest potential efficacy of immune training (IT)-based approaches for protection against severe lower respiratory tract infections in infants, but underlying mechanisms are unclear.

Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009–2017

Respiratory syncytial virus (RSV) and influenza are important causes of disease in children and adults. In Australia, information on the burden of RSV in adults is particularly limited.

Epidemiology of Neonatal Acute Respiratory Distress Syndrome: Prospective, Multicenter, International Cohort Study

Age-specific definitions for acute respiratory distress syndrome (ARDS) are available, including a specific definition for neonates (the "Montreux definition"). The epidemiology of neonatal ARDS is unknown. The objective of this study was to describe the epidemiology, clinical course, treatment, and outcomes of neonatal ARDS.

Temporal analysis of respiratory virus epidemics in Victoria over winter 2024

During winter months of temperate regions, concurrent epidemics of multiple respiratory pathogens can occur, causing periods of increased clinical burden. Case time series, which are predominantly used to monitor infection levels, can exhibit substantial noise and day-of-the-week effects, limiting the visual interpretation of trends in raw data.

Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab Prophylaxis

Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.

Longitudinal analysis of respiratory outcomes among bauxite exposed workers in western Australia

This study investigated any associations between cumulative bauxite exposure and respiratory symptoms.

An international cohort study of birth outcomes associated with hospitalized acute respiratory infection during pregnancy

Acute respiratory or febrile illness hospitalization during pregnancy was associated with increased risk of preterm birth and low birthweight birth

Nasal Cytokine Profiles of Patients Hospitalised with Respiratory Wheeze Associated with Rhinovirus C

Medically attended RV-C-induced wheeze is characterised by a Th2 inflammatory pattern, independent of viral load

Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85

The effects of OM-85 were strongest in the first winter season, with a trend for fewer children in the OM-85 group to have sLRIs and URIs